Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Arena Pharmaceuticals (NasdaqNM:ARNA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
July 23Conference call: Arena Pharmaceuticals, Inc. Earnings (Q2 2001)
Location
6166 Nancy Ridge Drive
San Diego, CA 92121
Phone: (858) 453-7200
Fax: (858) 453-7210
Email: invest@arenapharm.com
Employees (last reported count): 122
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 67%
·Over the last 6 months:
 · one insider buy; 31.0K shares (0.1% of insider shares)
 · 14 insider sells; 3.83M shares
  (17.2% of insider shares)
·Institutional: 59% (178% of float)
(142 institutions)
·Net Inst. Buying: 6.31M shares (+27.99%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Arena Pharmaceuticals, Inc. has developed a technology, Constitutively Activated Receptor Technology (CART), designed to identify drug-like compounds more efficiently than traditional drug discovery techniques. CART allows the Company to develop novel biochemical assays to discover drug-like compounds that target G protein-coupled receptors (GPCRs), an important class of receptors. Additionally, CART may be applicable to other human receptor classes, such as tyrosine kinase receptors (TKRs), as well as to non-human receptors, for the discovery of animal therapeutics and agricultural products.
More from Market Guide: Expanded Business Description

Financial Summary
ARNA is the developer of CART, a technology used to discover chemical compounds that act on a class of drug targets called G protein-coupled receptors. For the six months ended 6/30/01, revenues totaled $8.7 million, up from $1.3 million. Net loss applicable to Comm. fell 93% to $2.1 million. Revenues reflect research funding, milestone payment, and technology access fees in collaborations with Eli Lilly and Taisho. Lower losses also reflect the absence of a $22.4 million preferred stock charge.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Jack Lief, 55
Pres, CEO, Director
$322K$20K
Joseph Mooney, 53
CFO
--  --  
Richard Burgoon, Jr., 39
Sr. VP, Operations, Gen. Counsel and Sec.
233K45K
Robert Hoffman, 35
VP-Fin.
--  --  
Dominic Behan, Ph.D., 37
VP, Research
255K20K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ARNAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 10-Jan-2001
$11.563
Recent Price$14.20 
52-Week High
on 1-Sep-2000
$46.563
Daily Volume (3-month avg)466.5K
Daily Volume (10-day avg)437.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-66.1%
52-Week Change
relative to S&P500
-54.5%
Share-Related Items
Market Capitalization$391.3M
Shares Outstanding27.6M
Float9.10M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$9.88 
Earnings (ttm)-$0.13 
Earnings (mrq)-$0.14 
Sales (ttm)$0.72 
Cash (mrq)$8.09 
Valuation Ratios
Price/Book (mrq)1.44 
Price/EarningsN/A 
Price/Sales (ttm)19.84 
Income Statements
Sales (ttm)$15.1M
EBITDA (ttm)-$5.14M
Income available to common (ttm)-$2.41M
Profitability
Profit Margin (ttm)-16.0%
Operating Margin (ttm)-69.5%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-1.56%
Return on Equity (ttm)-1.72%
Financial Strength
Current Ratio (mrq)81.99 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$222.9M
Short Interest
As of 8-Aug-2001
Shares Short1.40M
Percent of Float15.4%
Shares Short
(Prior Month)
787.0K
Short Ratio2.78 
Daily Volume504.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.